CAIX靶向PET/CT评估透明细胞肾细胞癌:与[18F]FDG PET/CT头对头比较
前瞻性单中心研究纳入61例患者,对比新型CAIX靶向示踪剂[18F]AlF-NYM005与[18F]FDG PET/CT在透明细胞肾细胞癌中的诊断性能与分期。结果显示[18F]AlF-NYM005对肾脏肿瘤和转移灶的检出均优于[18F]FDG,并改变约三分之一患者的分期/再分期。
要点
- [18F]AlF-NYM005对肾脏肿瘤诊断灵敏度82.1%、特异度85.7%,均显著高于[18F]FDG的42.9%。
- [18F]AlF-NYM005检出转移灶248个,显著多于[18F]FDG的156个。
- [18F]AlF-NYM005使约三分之一患者的分期/再分期发生改变。
核心结论
- [18F]AlF-NYM005 PET/CT在肾脏肿瘤和转移灶检出方面优于[18F]FDG,示踪剂摄取更高且分期更准确。
研究设计与样本
- 前瞻性单中心试验纳入61例患者(41男20女,中位年龄62.0岁),一周内完成两种PET/CT。
- 以组织病理学、随访或多模态影像组成的复合参考标准定义331个病灶(35个肾脏、296个转移)。
主要发现
- 肾脏肿瘤中[18F]AlF-NYM005的灵敏度82.1%对42.9%、特异度85.7%对42.9%、阳性预测值95.8%对75.0%、阴性预测值54.5%对15.8%、准确率82.9%对42.9%(P<0.001)。
- [18F]AlF-NYM005检出转移灶248个,显著多于[18F]FDG的156个(P<0.001),尤其在淋巴结、胸膜/腹膜和肺。
- [18F]AlF-NYM005使约三分之一患者的分期/再分期发生改变。
- 肾脏肿瘤SUVmax为11.8对3.5,转移灶为5.0对3.2,肿瘤/肝脏比值为3.9对1.6。
- 免疫组化显示66.7%样本CAIX中/强表达,与[18F]AlF-NYM005摄取、pT分期及WHO/ISUP分级正相关。
关键数值与推荐
- 肾脏肿瘤诊断性能比较P<0.001,[18F]AlF-NYM005灵敏度82.1%、特异度85.7%、准确率82.9%。
- 转移灶检出数248对156,P<0.001。
- SUVmax:肾脏肿瘤11.8对3.5,转移灶5.0对3.2;肿瘤/肝脏比值3.9对1.6。
- 66.7%样本CAIX中/强表达,与摄取、pT分期及WHO/ISUP分级正相关。
临床怎么用
- CAIX靶向[18F]AlF-NYM005 PET/CT可用于透明细胞肾细胞癌的原发灶检出、转移灶评估和分期/再分期。
- 对[18F]FDG阴性或诊断不明确的肾脏肿瘤,可考虑CAIX靶向PET/CT以提高检出。
局限性
- 单中心前瞻性设计,样本量61例,结论需多中心验证。
- 试验为回顾性注册(ChiCTR2400085765,2024年6月18日注册)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the diagnostic performance and staging of the novel CAIX-targeted tracer [18F]AlF-NYM005 in clear cell renal cell carcinoma (ccRCC), and directly compare it with that of [18F]FDG PET/CT. METHODS: This prospective single-center trial enrolled 61 patients (41 male, 20 female; median age, 62.0 years). Participants underwent [18F]AlF-NYM005 and [18F]FDG PET/CT within one week. A composite reference standard including histopathology, follow-up, or multimodal imaging was used to define 331 lesions (35 renal, 296 metastatic). Diagnostic performance, standardized uptake value (SUV) and tumour-node-metastasis (TNM) classifications were evaluated and compared between the two tracers. RESULTS: For renal tumours, [18F]AlF-NYM005 PET/CT demonstrated significantly superior diagnostic performance to [18F]FDG (P < 0.001), with higher sensitivity (82.1% vs. 42.9%), specificity (85.7% vs. 42.9%), positive predictive value (95.8% vs. 75.0%), negative predictive value (54.5% vs. 15.8%), and accuracy (82.9% vs. 42.9%). In metastatic lesions, [18F]AlF-NYM005 detected significantly more lesions (248 vs. 156, P < 0.001), particularly in lymph nodes, pleura/peritoneum, and lung. Compared with [18F]FDG, [18F]AlF-NYM005 PET/CT consequently altered the staging/restaging of approximately one-third of patients. Quantitative analysis demonstrated higher tumour uptake (SUVmax) with [18F]AlF-NYM005 in renal tumours (11.8 vs. 3.5) and metastatic lesions (5.0 vs. 3.2), along with a higher tumour-to-liver ratio (3.9 vs. 1.6). Immunohistochemistry showed that 66.7% of samples had intermediate/strong CAIX expression, which was positively correlated with [18F]AlF-NYM005 uptake, pT stage, and WHO/ISUP grade. CONCLUSION: [18F]AlF-NYM005 PET/CT was superior to [18F]FDG in the detection of renal tumours and metastatic lesions, demonstrating higher radiotracer uptake and more accurate staging. TRIAL REGISTRATION: Chinese Clinical Trial Registry. ChiCTR2400085765, Registered 18 June 2024, retrospectively registered.
引用
- Guo W, Cheng L, Zhou X, et al. CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2026. PMID: 41629415. doi:10.1007/s00259-025-07748-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。